Clinical Trial Update: Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating modified release AFQ056 for Parkinson's patients with L-dopa induced dyskinesias has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesias
• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dyskinesias, Parkinson Disease | Phase 2 | Status: COMPLETED